Comparison the efficacy of neoadjuvant endocrine therapy and neoadjuvant chemotherapy for hormone receptor positive/human epidermal growth factor receptor 2 negative breast cancer
Objective To compare the efficacy of neoadjuvant endocrine therapy and neoadjuvant chemotherapy for hormone receptor(HR)positive(+)/human epidermal growth factor receptor 2(HER2)negative(-)breast cancer.Meth-od According to different treatment methods,110 HR+/HER2-breast cancer patients were divided into control group and observation group,with 55 cases in each group.The patients in the control group were received neoadjuvant chemo-therapy,while the patients in the observation group were received neoadjuvant endocrine therapy.The clinical efficacy,tu-mor markers[carbohydrate antigen 125(CA125),carbohydrate antigen 15-3(CA15-3)]levels,Ki-67 expression,risk of poor prognosis[preoperative endocrine prognostic index(PEPI)],and incidence of adverse reactions were compared be-tween two groups.Result The total effective rate of the observation group was 85.45%,which was higher than 69.09%in the control group,and the difference was statistically significant(P<0.05).After treatment,the high expression rate of Ki-67 in the observation group was lower than that in the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of serum CA125 and CA15-3 in both groups were lower than those before the treatment,the levels of serum CA125 and CA15-3 in the observation group were lower than those in the control group,and the dif-ferences were statistically significant(P<0.05).The incidence of high-risk poor prognosis in the observation group was 12.73%,which was lower than 32.73%in the control group,and the total incidence of adverse reactions was 7.27%,which was lower than 36.36%in the control group,and the differences were statistically significant(P<0.05).Conclusion The efficacy and prognosis of neoadjuvant endocrine therapy for HR+/HER2-breast cancer patients are better than neoad-juvant chemotherapy,which can inhibit the expression of Ki-67,reduce tumor marker levels,and have higher safety.
万方数据
维普
